ResMed (RMD) analyst forecast and price target
Analyst forecast
Consensus of 30 analyst ratings
Based on 6 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| RBC Capital | Upgraded | Sector Perform → Outperform | $262.00 from $244.00 | Sep 15, 2026 |
| Keybanc | Maintained | Overweight | $267.00 from $255.00 | Aug 31, 2026 |
| Rothschild & Co | Initiated Coverage | Neutral | $230.00 | Aug 19, 2026 |
| Keybanc | Maintained | Overweight | $255.00 from $260.00 | Aug 7, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $215.00 from $225.00 | Aug 7, 2026 |
| Piper Sandler | Maintained | Neutral | $225.00 from $233.00 | Aug 7, 2026 |
| RBC Capital | Maintained | Sector Perform | $244.00 from $234.00 | Aug 7, 2026 |
| Mizuho | Maintained | Outperform | $220.00 from $235.00 | Jul 15, 2026 |
| Citigroup | Downgraded | Buy → Neutral | $235.00 from $270.00 | Jul 13, 2026 |
| Jefferies | Maintained | Hold | $225.00 from $240.00 | Jul 10, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $225.00 from $227.00 | Jul 8, 2026 |
| RBC Capital | Maintained | Outperform | $276.00 from $321.00 | Jul 8, 2026 |
| Keybanc | Maintained | Overweight | $266.00 from $290.00 | Jun 22, 2026 |
| Morgan Stanley | Downgraded | Overweight → Equal-Weight | $230.00 from $286.00 | Jun 17, 2026 |
| Citigroup | Maintained | Buy | $270.00 from $340.00 | Jun 15, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $227.00 from $270.00 | May 1, 2026 |
| RBC Capital | Maintained | Outperform | $321.00 from $314.00 | May 1, 2026 |
| Keybanc | Maintained | Overweight | $290.00 from $302.00 | Apr 27, 2026 |
| JP Morgan | Maintained | Overweight | — | Apr 15, 2026 |
| Citigroup | Maintained | Buy | $340.00 from $345.00 | Apr 9, 2026 |
Frequently asked questions
What is the price target for RMD stock?
The average 12-month analyst price target for ResMed (RMD) is $236.50, with a high estimate of $267.00 and a low of $215.00, across 6 analysts.
Is RMD a buy, sell, or hold?
Analysts covering ResMed currently average a Buy rating: 17 buy, 10 hold and 3 sell, from 30 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for RMD?
The average price target of $236.50 implies 0.51% upside from the last price of $235.29.
What is the latest analyst rating on RMD?
On Sep 15, 2026, RBC Capital upgraded ResMed to Outperform with a price target of $262.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.